Why colchicine, and why now?

We’ve chased the inflammatory axis of atherosclerosis for decades. An age old drug (colchicine) has emerged as a pragmatic anti-inflammatory add-on for secondary prevention in chronic coronary disease (CCD). Prior trials highlight both promise and caveats: benefits on composites largely driven by fewer urgent revascularizations (and stroke in COLCOT)(1–3).

---

What the key trials showed (and how they differ)

COLCOT (post-MI, median enrollment ~14 days)

Low-dose colchicine (0.5 mg daily) reduced the composite of CV death, resuscitated arrest, MI, stroke, or urgent angina-leading revascularization vs placebo. The effect was mainly carried by urgent revascularization and stroke reductions. Overall serious adverse events were similar, though pneumonia was numerically higher with colchicine (1).

LoDoCo2 (stable CAD)

In stable CAD (median follow-up ~29 months; run-in to exclude intolerance), colchicine 0.5 mg daily lowered MACE (HR ~0.69), mainly via MI and ischemia-driven revascularization. Signals for higher non-CV mortality were noted but not definitive (2).

COPS (ACS)

Randomized ACS cohort at discharge showed no significant reduction of the composite endpoint and a concerning signal for non-CV death in the colchicine arm, tempered by fewer urgent revascularizations. Net clinical meaning: mixed (3).

Why LoDoCo2 looks “more positive” than COPS: population (stable vs ACS), longer follow-up and larger N in LoDoCo2, and LoDoCo2’s run-in (better tolerability selection) all pull the absolute risk curves apart in favor of colchicine.

---

What’s new in the past 3 years?

• Guidelines changed
  • ACC/AHA 2023 CCD guideline: consider low-dose colchicine 0.5 mg daily in select patients with residual risk (Class IIb, LOE B-R) (4).
  • ESC 2024 CCS guideline: upgraded to Class IIa, LOE A for CCD—broader endorsement than ACC/AHA (5).
• Regulatory milestone
  The FDA review dossier for colchicine (NDA 215727) summarized LoDoCo/LoDoCo2 efficacy and safety, supporting approval in 2023 as the first anti-inflammatory agent for ASCVD prevention (6).
• Fresh analyses from LoDoCo2
  A 2025 JAHA secondary analysis suggested consistent relative and absolute benefit across baseline risk strata—i.e., not limited to the very high-risk tail (7).
• Meta-analyses / perspectives
  Pooled analyses continue to show MACE reduction with low-dose colchicine and no consistent increase in all-cause or non-CV mortality when all data are considered, though heterogeneity remains (8).
• Colchicine in diabetes pipelines
  The COLCOT-T2D program is underway to test primary prevention in type 2 diabetes (without known CAD). Not practice-changing yet, but it may broaden the conversation if positive (9).

---

LoDoCo vs COLCOT

• Setting: LoDoCo2 = stable CCD; COLCOT = recent MI.
• Primary driver: LoDoCo2 mainly MI and ischemia-driven revascularization; COLCOT adds a stroke signal.
• Safety lens: Both trials demand vigilance for infection and GI intolerance. LoDoCo2 raised non-CV death concerns, but pooled analyses and regulatory reviews are more reassuring (6,8).
• Bio-markers: Interestingly, LoDoCo showed significant reductions in CRP and IL-6 levels, and COLCOT actually couldn’t give a statistically significant reduction in these levels.

---

Practical Pearls (aligned with new guidance)

1. Who to consider: CCD patients with residual risk despite statin/ezetimibe/PCSK9 and optimal antithrombotic therapy; especially those with recurrent events or diffuse disease (4,5).
2. Dose/formulation: 0.5 mg once daily.
3. Avoid / caution: advanced CKD, hepatic disease, strong CYP3A4/P-gp inhibitors, cytopenias, recurrent infection.
4. Set expectations: benefit is modest but real and accrues over time; GI intolerance is commonest reason to stop; counsel on infection vigilance.
5. ACS vs stable: data strongest in stable CCD (LoDoCo2). In recent ACS, net benefit is less certain (COPS neutral; COLCOT positive but composite-driven). Individualize.

---

My Take

Colchicine has matured from “interesting anti-inflammatory” to guideline-endorsed option for secondary prevention. LoDoCo2 provides the most compelling long-term data in stable CCD; COLCOT broadens applicability post-MI; COPS reminds us ACS patients are not the same. The safety lens remains key, particularly infections and non-CV mortality signals, but the balance of evidence now favors carefully selected use. The ongoing diabetes and imaging-based studies will help clarify its future role. With the fact that stable patients had significant reduction in inflammatory biomarkers, I will be sure to follow these in patients whom I start on the therapy.

---

TLDR

• COLCOT (2019): Post-MI, ↓ composite events, mainly stroke & urgent revasc.
• LoDoCo2 (2020): Stable CAD, ↓ MACE, benefit on MI & revasc, mortality signal debated.
• COPS (2020): ACS at discharge, neutral, ↑ non-CV death.
• Guidelines: ACC/AHA 2023 IIb, ESC 2024 IIa. FDA approved colchicine 0.5 mg in 2023 for ASCVD prevention.
• Clinical message: Low-dose colchicine reduces MACE in stable CAD; select carefully in ACS; watch safety signals.

---

References

1. Tardif J-C, et al. COLCOT. N Engl J Med. 2019;381:2497-2505.
2. Nidorf SM, et al. LoDoCo2. N Engl J Med. 2020;383:1838-1847.
3. Tong DC, et al. COPS. Circulation. 2020;142:1890-1900.
4. ACC/AHA Task Force. 2023 Chronic Coronary Disease Guideline. J Am Coll Cardiol. 2023.
5. ESC Guidelines for Chronic Coronary Syndromes. Eur Heart J. 2024.
6. FDA. NDA 215727: Lodoco (colchicine 0.5 mg) review dossier. 2023.
7. JAHA. LoDoCo2 secondary analysis. 2025.
8. Meta-analyses of colchicine in CAD (PMC/JAHA 2022–24).
9. ClinicalTrials.gov. COLCOT-T2D ongoing.